Talaris Therapeutics (NASDAQ:TALS – Get Rating) and Pluri (NASDAQ:PLUR – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Profitability

This table compares Talaris Therapeutics and Pluri's net margins, return on equity and return on assets.

Volatility & Risk

Talaris Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.

Insider & Institutional Ownership

Earnings & Valuation

This table compares Talaris Therapeutics and Pluri's top-line revenue, earnings per share and valuation.

Pluri has higher revenue and earnings than Talaris Therapeutics.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Talaris Therapeutics and Pluri, as reported by MarketBeat.

Talaris Therapeutics currently has a consensus target price of $14.80, indicating a potential upside of 1,103.25%. Given Talaris Therapeutics' higher possible upside, research analysts plainly believe Talaris Therapeutics is more favorable than Pluri.

Summary

Talaris Therapeutics beats Pluri on 7 of the 9 factors compared between the two stocks.

About Talaris Therapeutics

(Get Rating)

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

About Pluri

(Get Rating)

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation; and a solution for the treatment of acute radiation syndrome through its collaboration in the United States with the National Institutes of Health and the U.S. Department of Defense. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.